OBJECTIVE: To evaluate the efficacy, safety and economy of tirofiban in the treatment of acute ischemic stroke based on rapid health technology assessment(HTA), so as to provide evidence-based basis for clinical rational drug use. METHODS: Domestic and foreign databases such as PubMed, the Cochrane Library, CNKI and Wanfang Data were retrieved to collect HTA reports, systematic review / Meta-analysis and pharmacoeconomic studies of tirofiban in the treatment of acute ischemic stroke ( the intervention group was treated with tirofiban alone or in combination with other treatment, the control group received placebo or other treatment). The retrieval time was from the establishment of the database to Sept. 2021. Two researchers independently screened the literature according to inclusion and exclusion criteria, extracted data, evaluated the literature quality, summarized the research results and analyzed qualitatively. RESULTS: A total of 15 systematic review / Meta-analysis were included. In terms of effectiveness, compared with the control group, tirofibancan could significantly improve patients’ neurological function and activity of daily living, with statistically significant difference (P< 0. 05); there was no statistically significant difference in the rate of reocclusion between two groups (P>0. 05); in terms of improving 90-day prognosis, vascular revascularization rate and mortality, the results of various studies were inconsistent. In terms of safety, compared with the control group, tirofiban did not increase the incidence of intracranial hemorrhage, the incidence of symptomatic intracranial hemorrhage, the conversion rate of intracranial hemorrhage, the incidence of intracranial parenchymal hematoma type 2 and the incidence of adverse bleeding events at other sites, and there was no statistical significance between two groups ( P > 0. 05); the incidence of fatal intracranial hemorrhage increased significantly in tirofiban group, which might be related to the route and dose of administration. CONCLUSIONS: Tirofiban has significant effectiveness and safety in the treatment of acute ischemic stroke. Due to the significant increase in the incidence of fatal intracranial hemorrhage of tirofiban, more large-scale, multicenter randomized controlled studies can be considered in the future to further confirm the safety of tirofiban in the treatment of ischemic stroke and provide reference for clinical and decision-makers. [ABSTRACT FROM AUTHOR]